---
title: "WEIGUANG BIOLOGICAL plans to invest CNY 2.308 billion to build an intelligent industrial base in Guangming District, Shenzhen, to expand production capacity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249130903.md"
description: "WEIGUANG BIOLOGICAL plans to invest CNY 2.308 billion in the Guangming District of Shenzhen to build an intelligent industrial base. The project includes facilities such as dormitories, factories, and warehouses, aimed at meeting the production needs of blood products, with a designed annual processing capacity of 1,200 tons of plasma. This project will help the company expand its production scale and increase its market share"
datetime: "2025-07-18T10:53:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249130903.md)
  - [en](https://longbridge.com/en/news/249130903.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249130903.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/249130903.md) | [繁體中文](https://longbridge.com/zh-HK/news/249130903.md)


# WEIGUANG BIOLOGICAL plans to invest CNY 2.308 billion to build an intelligent industrial base in Guangming District, Shenzhen, to expand production capacity

According to the announcement from Dolphin Research, WEIGUANG BIOLOGICAL (002880.SZ) stated that the company's board of directors has approved the proposal for investing in the WEIGUANG BIOLOGICAL Intelligent Industrial Base Project. The project is located in the Guangming District of Shenzhen, and its main construction content includes the building of dormitory buildings, multiple factories, a comprehensive warehouse, an ethanol recovery station, a hazardous materials warehouse, a hazardous waste warehouse, an ethanol underground tank area, and a sewage treatment station, to meet the operational needs of blood product manufacturing enterprises; the second phase reserves space for high-rise factory construction to create a modern intelligent industrial base, meeting the company's production and operational needs; the designed capacity is to process 1,200 tons of plasma annually. The total investment for the project is 2.308 billion yuan.

The announcement stated that the implementation of this project is beneficial for the company to seize market opportunities, further alleviate the supply-demand contradiction in the industry, expand production scale, and enhance market share

### Related Stocks

- [WEIGUANG BIOLOGICAL (002880.CN)](https://longbridge.com/en/quote/002880.CN.md)

## Related News & Research

- [10:00 ETSanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence](https://longbridge.com/en/news/281035304.md)
- [Samsung Heavy Industries Wins Two Very Large Gas Carrier Orders from Bermudan Client; Shares Jump 10%](https://longbridge.com/en/news/281321636.md)
- [PetroChina Renews Financial Deal With Related Company](https://longbridge.com/en/news/280998322.md)
- [China Youran Dairy Further Delays Circular on Share Subscription and Whitewash Waiver](https://longbridge.com/en/news/281536370.md)
- [Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst⢠(bumetanide nasal spray)](https://longbridge.com/en/news/281570860.md)